DEVELOPMENT AND VALIDATION OF CHROMATOGRAPHIC METHOD FOR THE SIMULTANEOUS ESTIMATION OF OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE, CILNIDIPINE IN COMBINATION TABLET DOSAGE FORM

Authors

  • Ravichandran S PSG college of pharmacy, Peelamedu, Coimbatore - 4
  • Valliappan K Department of Pharmacy, Annamalai University, Chidambaram
  • Ramanathan M PSG College of Pharmacy

Keywords:

HPLC, Acetonitrile, Olmesartan, Amlodipine, Cilnidipine

Abstract

Objective: To develop and validate a simple, sensitive and isocratic reverse phase high performance liquid chromatography (RP-HPLC) method for the simultaneous determination of olmesartan medoxomil (OLM), amlodipine besylate (AML) and cilnidipine (CIL) in pharmaceutical tablet formulation.

Methods: In this work we have taken 2 combinations, combination 1-OLM & AML and combination 2-OLM & CIL. HPLC analysis was carried out by using reverse phase isocratic elution with a C 18 column and a mobile phase of 0.05 M ammonium acetate, acetonitrile and methanol in the ratio of 30:50:20, v/v, pH was adjusted to 7.3. Detection of the analyte was achieved by using UV detector at 240 nm.

Results: The retention time of olmesartan medoxomil, amlodipine besylate and cilnidipine were 2.2, 3 and 4.5 minutes respectively. Linearity of the method was found to be in the concentration range of 10-100µg/ml for olmesartan medoxomil, 5-50µg/ml for amlodipine and 10-100µg/ml for cilnidipine. The correlation coefficient value was greater than 0.999 for all the analytes.

Conclusion: The method was validated as per ICH guidelines and is applied for the estimation of these components simultaneously in pharmaceutical tablet formulation.

 

Downloads

Download data is not yet available.

References

Kobayashi N, Fujimori I, Watanabe M, Iked T. Real-time monitoring of metabolic reactions by microdialysis in combination with tandem mass spectrometry: hydrolysis of CS-866 in vitro in human and rat plasma, livers, and small intestines. Anal Biochem 2000;287:272-8.

Koike H, Konse T, Sada T, Ikeda T, Hyogo S, Hinman D, et al. Olmesartan medoxomil, a novel potent angiotensin II blocker. Ann Rep Sankyo Res Lab 2003;55:1-91.

Mire D, Silfani TN, Pugsley MK. A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker. J Cardiovasc Pharmacol 2005;46:585-93.

Puchler K, Nussberger J, L Laeis P, Witte PU, Brunner HR. Blood pressure and endocrine effects of single doses of CS-866, a novel angiotensin II antagonist, in salt-restricted hypertensive patients. J Hypertens 1997;15:1809-12.

Brousil JA, Burke J. Olmesartan medoxomil: an angiotensin II-receptor blocker. Clin Ther 2003;25(4):1041-55.

Takemoto M, Egashira K, Tomita H, Usui M, Okamoto H, Kitabatake A, et al. A Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade: effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis. Hypertension 1997;30:1621-7.

Igarashi K, Hotta K, Kasuya F, Abe K. Determination of cabergoline and L-dopa in human plasma using liquid chromatography–tandem mass spectrometry. J Chromatgr B 2003;792:55-61.

Kimball BA, Deliberto TJ, Johnson JJ. Determination of cabergoline by electrospray ionization tandem mass spectrometry: picogram detection via column focusing sample introduction. Anal Chem 2001;73:4972-6.

Indian Pharmacopoeia. The Indian pharmacopoeia commission, India; 2007;2:714-6.

British Pharmacopoeia. The department of health. Great Britain 2008;1:137-8.

Goodman AG, Gilman LS. The Pharmacological basis of therapeutics. 8th edition. Paragon Press Oxford; 1990. p. 774.

Sweetman SC. Martindale the complete drug reference. 34th edition. Pharmaceutical Press, London; 2005. p. 862-6.

Dollery C. Therapeutic drugs. 2ndedition. UK: Churchill Livingstone; 1999. p. 151.

Abernethy DR. The pharmacokinetic profile of amlodipine. Am Heart J 1989:118:1100-3.

Meredith PA, Elliott HL. Clinical pharmacokinetics of amlodipine. Clin Pharmacokinet 1992;22:22-31.

Pankaj P Chaudhari, Bhalerao AV. Method validation for spectrophotometric estimation of cilnidipine. Int J Pharm Pharm Sci 2012;5:96-8.

Uneyama H, Uchida H, Konda T, Yoshimoto R. Cilnidipine: preclinical profile and clinical evaluation. Cardiovasc Drug Rev 1999;17:341-57.

Zaman ZA, Kumari V. Comparison of the effects of amlodipine and cilnidipine on blood pressure, heart rate, proteinuria and lipid profile in hypertensive patients. Int J Basic Clin Pharmacol 2013;2:160-4.

Rao JR, Rajput MP, Yadav SS, Mull TS, Bharekar VV. Simultaneous quantitation of olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide in pharmaceutical dosage form by using HPLC. Int J Pharm Tech Res 2011;3:1435-40

Jain PS, Patel MK, Gorle AP, Chaudhari AJ, Surana SJ. Stability-Indicating method for simultaneous estimation of Olmesartan Medoxomile, Amlodipine Besylate and Hydrochlorothiazide by RP-HPLC in tablet dosage form. J Chromatogr Sci 2012;50:680-7.

Minase AS, Dole MN, Sawant SD. Development and validation of analytical method for simultaneous estimation of cilnidipine and olmesartan medoxomil in bulk and tablet dosage form by RP-HPLC. Int J Pharm Pharm Sci 2014;6:508-11.

Validation of Analytical procedure, Text and methodology. International conference on Harmonization ICH Q2(R1); 2005.

Published

01-07-2015

How to Cite

S, R., V. K, and R. M. “DEVELOPMENT AND VALIDATION OF CHROMATOGRAPHIC METHOD FOR THE SIMULTANEOUS ESTIMATION OF OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE, CILNIDIPINE IN COMBINATION TABLET DOSAGE FORM”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 7, no. 7, July 2015, pp. 321-4, https://www.innovareacademics.in/journals/index.php/ijpps/article/view/5856.

Issue

Section

Original Article(s)